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CD20 antibody depletion of B lymphocytes effectively ameliorates
multiple T cell-mediated autoimmune diseases through mechanisms
that remain unclear. To address this, a mouse CD20 antibody that
depletes >95% of mature B cells in mice with otherwise intact
immune systems was used to assess the role of B cells in CD4 and
CD8 T cell activation and expansion in vivo. B cell depletion had no
direct effect on T cell subsets or the activation status of CD4 and
CD8 T cells in naive mice. However, B cell depletion impaired CD4
T cell activation and clonal expansion in response to protein antigens
and pathogen challenge, whereas CD8 T cell activation was not
affected. In vivo dendritic cell ablation, along with CD20 immuno-
therapy, revealed that optimal antigen-specific CD4 T cell priming
required both B cells and dendritic cells. Most importantly, B cell
depletion inhibited antigen-specific CD4 T cell expansion in both
collagen-induced arthritis and autoimmune diabetes mouse models.
These results provide direct evidence that B cells contribute to T cell
activation and expansion in vivo and offer insights into the mecha-
nism of action for B cell depletion therapy in the treatment of
autoimmunity.
autoimmune disease  B lymphocyte  immunotherapy  antigen presentation
Central defects in T lymphocyte regulation contribute to mostautoimmune diseases (1). Surprisingly however, mAb therapy
directed against the CD20 cell surface molecule of human B cells
(rituximab) has shown varying degrees of efficacy in rheumatoid
arthritis, idiopathic thrombocytopenic purpura, hemolytic anemia,
lupus erythematosus, and pemphigus vulgaris treatment (2, 3).
Despite the benefits of this immunotherapy, the cellular and
molecular basis for the protective effect mediated by B cell deple-
tion is unknown (4). Understanding the mechanisms underlying the
therapeutic benefit of B cell depletion is complicated by the fact that
B cells not only produce autoantibodies (5) but also release
inflammatory or immunomodulatory cytokines (6), regulate lym-
phoid tissue neogenesis and structure, provide costimulatory sig-
nals, alter dendritic cell (DC) function and homeostasis (7), can
function as antigen-presenting cells, promote naı̈ve CD4 T cell
differentiation into Th1 or Th2 subsets, and may influence
regulatory T cell numbers and function (8).
Examining the effects of B cell depletion in mice with intact
immune systems is possible by using mouse anti-mouse CD20 mAbs
in which B cells are depleted in vivo by monocyte-mediated
antibody-dependent cellular cytotoxicity (9, 10). More than 95% of
mature B cells in blood and primary lymphoid organs are depleted
after 2 days by a single dose of CD20 mAb (MB20-11, 250 g per
mouse), with the effect lasting 8 weeks (11). B cell depletion
prevents autoimmunity in mouse models of collagen-induced ar-
thritis (CIA) (12), scleroderma (13), Sjogren’s syndrome (14), and
diabetes in nonobese diabetic (NOD) mice (Y. Xiu, C. P. Wong,
J.-D.B., Y. Hamaguchi, Y.W., S. M. Pop, R.M.T., and T.F.T.,
unpublished work). In these models, B cell depletion after disease
onset is less beneficial, indicating a possible role for B cells in the
early stages of autoimmunity during autoreactive T cell activation
and/or expansion. The effect of B cell depletion on T cell activation
in vivo was therefore assessed to identify mechanisms by which B
cell depletion ameliorates T cell-dependent autoimmune disease.
Results
CD20 Expression Is B Cell-Restricted in Mice. CD20 mAb treatment
depleted the majority of B220 B cells on days 7 and 28, whereas
absolute numbers of other leukocyte subsets in all primary lym-
phoid organs were not affected (Table 1). Although a small subset
of human T and natural killer cells has been reported to be depleted
after CD20 mAb therapy in rheumatoid arthritis patients as a result
of low-level CD20 expression (15, 16), immunofluorescence stain-
ing of all leukocytes subsets revealed that CD20 expression is B cell
restricted in mice [supporting information (SI) Fig. 5], as in humans
(17). Thereby, CD20 mAb treatment was unlikely to modify auto-
immune responses by depleting functionally important non B cell
leukocyte subsets.
B Cell Depletion Does Not Affect Serum Cytokine Levels and T Cell
Phenotypes or Functional Capacity. Whether B cell depletion and/or
monocyte activation could influence serum cytokines that in turn
may modify T cell function was examined. CD20 mAb treatment
did not significantly alter serum IL-1, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12, IL-13, IL-17, TNF-, IFN-, GM-CSF, or TGF-1 levels
over the course of a week (SI Fig. 6A and data not shown).
Therefore, B cell depletion was unlikely to induce a systemic
cytokine release that altered T cell function.
To assess possible indirect effects of CD20 mAb treatment on T
cells, expression of activation markers by CD4 and CD8 T cells
was examined. Expression of CD25, CD28, CD18, CD69, CD40L,
OX40, or CTLA-4 by spleen or lymph node CD4 or CD8 T cells
was unaffected by B cell depletion over 7 and 28 days (SI Fig. 6B
and data not shown). Likewise, B cell depletion did not impair the
capacity of spleen or lymph node CD4 T cells to proliferate and
produce cytokines in vitro after polyclonal stimulation (SI Fig. 6C
and data not shown). To rule out more subtle effects on T cells,
monocytes, and DCs after B cell depletion, gene expression profiles
were assessed by quantitative real-time PCR analysis. Transcripts
for 84 genes related to T cell activation and differentiation were
analyzed by using B220 splenocytes from mice treated 4 days
earlier with CD20 or control mAb. B cell depletion did not alter
transcript levels for any of the 84 genes analyzed (SI Fig. 6D and
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data not shown). Thus, in vivo B cell depletion did not significantly
affect CD4 T cell phenotypes, functional capacity, or gene ex-
pression profiles.
B Cell Depletion Inhibits Antigen-Specific CD4 T Cell Expansion and
Activation in Vivo. To evaluate the impact of B cell depletion on T
cell responses to protein antigen challenge, B cell-depleted mice
were immunized with keyhole limpet hemocyanin (KLH), with
draining lymph node CD4 and CD8 T cells being purified 7 days
later. Antigen-specific T cell proliferation was quantified in vitro by
using purified mitomycin C-treated B cells from control mAb-
treated littermates as antigen-presenting cells. CD4 T cell recall
responses to KLH in B cell-depleted mice were reduced by 71 
13% (P  0.01) at 1 g/ml KLH and 63  8% (P  0.01) at 10 g/ml
KLH compared with control mAb-treated littermates (Fig. 1A),
whereas antigen-specific CD8 T cell proliferation was unaffected.
The effect of B cell depletion on CD4 and CD8 T cell
responses in vivo was directly investigated by using ovalbumin
(OVA)-specific Thy1.1 CD4 and CD8 T cells prepared from
OT-II and OT-I transgenic mice, respectively (18, 19). 5-(and-6)-
carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled
OT-II CD4 and OT-I CD8 T cells were adoptively transferred
into CD20 or control mAb-treated littermates before immunization
with OVA. CD4 T cells proliferated similarly in B cell-depleted
and control mAb-treated littermates after immunization with high-
dose OVA (100 g; Fig. 1B). By contrast, CD4 T cell expansion
was significantly reduced in B cell-depleted mice compared with
control mAb treated littermates immunized with low doses of OVA
(at 10 g, 40  14% reduction, P  0.01; at 1 g, 75  33%
reduction, P  0.05). Heterogeneity in the frequency and extent of
T cell proliferation is likely to result from heterogeneity among T
cells, heterogeneous frequencies of T cells interacting with appro-
priate antigen-presenting DCs or B cells in vivo, and/or the strength/
duration of antigen-specific interactions. CD8 T cell proliferation
was identical in B cell-depleted and control mAb-treated litter-
mates at all OVA concentrations.
Whether B cells also influence T cell responses to pathogens was
assessed by infecting mice with a strain of Listeria monocytogenes
modified to secrete soluble OVA (20). Listeria replicate in macro-
phages and induce both CD4 and CD8 T cell responses (21).
Listeria infection induced robust CD4 and CD8 T cell reactivity
in control mAb-treated littermates, whereas B cell depletion sig-
nificantly reduced the frequency of dividing CD4 T cell prolifer-
ation (14  1% reduction; P  0.01) (Fig. 1C Left), and the extent
of CD4 T cell proliferation (evaluated by DFSE geometric mean
fluorescence decrease; Fig. 1C Right) but not CD8 T cell prolif-
eration. B cell depletion had no effect on mouse survival, consistent
with the rapid expansion of CD8 T cells after Listeria infection.
Moreover, characteristic of T effector cell generation, most CD4
T cells exhibited a CD62lowCD44high phenotype by day 7 after
Listeria infection in control mAb-treated mice (Fig. 2A). By con-
trast, CD44 up-regulation and CD62L down-regulation were sig-
nificantly reduced in B cell-depleted littermates (35  5% reduction
and 54  4% reduction, P  0.01, for CD44 and CD62L, respec-
tively) (Fig. 2A). IL-2 and IFN- production by CD4 T cells was
also significantly reduced in B cell-depleted littermates after Lis-
teria infection (for IL-2: 52  15% reduction, P  0.05; for IFN-:
82  6% reduction, P  0.01) (Fig. 2B and data not shown). Despite
Table 1. Lymphocyte populations after B cell depletion
Tissue and lymphocyte subset
7 days 28 days
Control mAb CD20 mAb Control mAb CD20 mAb
Blood
B220 4.0  0.9 0.013  0.002* 3.49  0.75 0.010  0.003*
CD4 1.7  0.4 1.2  0.2 1.2  0.1 1.3  0.2
CD4CD25FoxP3 0.6  0.1 0.6  0.2 0.75  0.08 0.9  0.2
CD8 0.8  0.2 0.6  0.1 0.7  0.07 0.7  0.1
NK1.1CD3 0.5  0.1 0.4  0.1 0.4  0.1 0.4  0.05
Spleen
B220 52.6  13.3 0.7  0.2* 70.4  10.6 0.27  0.01*
CD4 14.9  3.5 13.1  2.3 20.6  2.3 19.0  1.5
CD4CD44CD62L 3.4  0.8 2.9  1.1 3.1  0.3 3.1  0.4
CD4CD25FoxP3 1.6  0.2 1.4  0.1 2.1  0.3 1.9  0.1
CD8 7.8  1.6 6.8  1.6 9.7  1.3 9.0  1.1
CD8CD44CD62L 0.3  0.1 0.3  0.1 0.22  0.04 0.18  0.01
CD11chighCD8 3.4  0.1 3.8  0.1 3.5  0.1 3.6  0.1
CD11chighCD8 0.8  0.1 1.0  0.1 0.7  0.1 0.9  0.1
CD11cintPDCA-1B220 0.31  0.04 0.27  0.10 0.51  0.12 0.65  0.10
Peripheral LN
B220 8.6  1.2 0.09  0.01* 10.7  1.8 0.03  0.01*
CD4 12.3  1.5 11.6  2.3 15.4  0.9 16.8  2.2
CD4CD44CD62L 0.71  0.01 0.63  0.02 0.85  0.09 0.76  0.08
CD4CD25FoxP3 1.2  0.1 1.1  0.2 1.6  0.1 1.5  0.2
CD8 8.4  1.4 7.9  0.9 10.5  0.4 9.8  1.6
CD8CD44CD62L 0.04  0.01 0.05  0.01 0.05  0.01 0.06  0.01
Thymus
B220 0.17  0.01 0.05  0.01* 0.17  0.02 0.07  0.02*
CD4CD8 2.8  0.5 2.5  0.4 3.7  0.4 4.1  0.5
CD4CD8 96  24 76  12 137  20 175  10
CD4CD8 13  4 13  3 24  4 36  4
CD4CD8 3.3  0.5 2.4  0.3 4.8  0.6 5.6  0.6
The values (SEM) indicate cell numbers ( 106) present in tissues of at least four mice for each group either
7 or 28 days after mAb treatment (250 g). The differences between mean lymphocyte numbers in CD20 and
control mAb-treated littermates were significant: *, P  0.01.









this, B cell depletion did not significantly alter CD8 T cell
phenotypes or cytokine production after Listeria infection. Thus,
short-term B cell depletion significantly affects antigen-specific
CD4 T cell expansion, activation, and effector cell differentiation
in vivo.
B Cell and DC Interactions Regulate CD4 T Cell Expansion in Vivo. The
relative contributions of B cells and DCs to CD4 T cell priming in
vivo were compared by using B6.CD11c–DTR transgenic mice, a
mouse model for inducible DC ablation in vivo (22). A single
injection of diphtheria toxin (DT) (100 ng) into CD11c–DTR mice
induced a selective 10-fold depletion of conventional splenic DCs
after 10 h that persisted for 3 days (Fig. 3A). CD20 mAb-mediated
B cell depletion was similar in WT and B6.CD11c–DTR littermates
treated with DT (data not shown). B cell depletion significantly
reduced the frequency of dividing OT-II CD4 T cells after
Fig. 1. B cell depletion inhibits antigen-specific CD4
but not CD8 T cell expansion. (A) Impaired CD4 T cell
proliferation in B cell-depleted mice after KLH restimu-
lation in vitro. CD20 (open circles) or control (CTL) (filled
circles) mAb-treated mice were immunized with KLH.
Seven days later, CD4 (Left) or CD8 (Right) T cells were
purified from draining lymph nodes and cultured in vitro
with KLH and mitomycin C-treated B cells from control
mice. The values represent mean (SEM) [3H]thymidine
(TdR) uptake from triplicate cultures. (B) Impaired CD4
T cell proliferation in vivo in B cell-depleted mice after
low-dose OVA immunization. CD4 cells from OT-II
Thy1.1 mice or CD8 cells from OT-I Thy1.1 mice were
CFSE-labeled and transferred into Thy1.2 recipients
that had been treated with CD20 or control mAb 7 days
earlier. After adoptive transfers, the mice were immu-
nized with graded OVA doses (1, 10, and 100 g). Three
days later, splenocytes were harvested and stained to
analyze divisions of donor cells. The bar graphs show
CFSE geometric mean fluorescence of the whole histo-
gram, which is inversely proportional to cell divisions
(CD20 mAb, open bars; control mAb, closed bars). (C)
ImpairedCD4 Tcellproliferation inBcell-depletedmice
after Listeria infection. The same experimental protocols
were used as in B except that mice were infected 1 day
after T cell adoptive transfers with Listeria that secretes
OVApeptideandthat splenocyteswereharvested7days
after infection. All data are representative of two inde-
pendent experiments with at least three mice in each
group. Significant differences between sample means
are indicated: *, P  0.05; **, P  0.01.
Fig. 2. Impaired CD4 T cell activation after B cell
depletion. WT mice treated with CD20 or control (CTL)
mAb were infected with Listeria 7 days later. Splenocytes
were harvested 7 days after infection. (A) CD44 and
CD62L expression by CD4 and CD8 T cells. Flow cyto-
metric histograms from a representative mouse in each
group are shown. (Left and Center) Numbers denote the
percentage of CD4 (Left) and CD8 (Center) T cells that
were CD44high or CD62Llow. (Right) Bar graphs show
CD44 and CD62L geometric mean fluorescence intensi-
ties for CD4 and CD8 T cells (CD20 mAb, open bars;
control mAb, closed bars). (B) (Left and Center) Intracel-
lular IL-2 production by CD4 T cells (Left) and IFN-
production by CD8 T cells (Center) after Listeria infec-
tion. Flow cytometric histograms from a representative
mouse in each group are shown. (Right) The bar graph
denotes the percentage of CD4 and CD8 T cells that
produce IL-2 and IFN-, respectively (CD20 mAb, open
bars; CTL mAb, closed bars). All data are representative
of twoindependentexperimentswiththreemice ineach
group. Significant differences between sample means
are indicated: *, P  0.05; **, P  0.01.
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adoptive transfer (14  1% reduction; P  0.01) and the extent of
divisions of OT-II CD4 T cells in response to Listeria infection
(Fig. 3B). The absence of DCs in B6.CD11c–DTR mice also
reduced the frequency of proliferating OT-II CD4 T cells in
response to Listeria infection (33  4% reduction; P  0.01), and
also dramatically reduced the extent of CD4 T cell proliferation.
Combined B cell and DC depletion further inhibited the frequency
of proliferating OT-II CD4 T cells (76  9%; P  0.01) and almost
eliminated their proliferation extent after Listeria infection. By
contrast, only DC depletion significantly affected the proliferation
of adoptively transferred OT-I CD8 T cells in response to Listeria
infection (34  11% reduction; P  0.01) (Fig. 3C). Thus, DCs
alone were not capable of inducing optimal CD4 T cell responses
to a pathogen challenge.
B Cell Depletion Inhibits Autoantigen-Specific CD4 T Cell Prolifera-
tion. The effect of CD20 mAb treatment on autoreactive CD4 T
cell expansion was evaluated in murine models of autoimmune
diabetes (NOD mice) and arthritis, two T cell-dependent autoim-
mune diseases in which B cell-depletion significantly reduces dis-
ease severity (ref. 12 and Y. Xiu, C. P. Wong, J.-D.B., Y. Hamagu-
chi, Y.W., S. M. Pop, R.M.T., and T.F.T., unpublished work).
Five-week-old female NOD mice were treated with CD20 or
control mAb and then received an injection of CFSE-labeled CD4
T cells from transgenic BDC2.5 NOD mice. BDC2.5 T cells
proliferate in response to  cell autoantigens including glutamic
acid decarboxylase within the pancreatic lymph nodes of NOD mice
without any immunization (23). Four days after adoptive transfer,
CD20 mAb treatment had no effect on the numbers of BDC2.5
CD4 T cells migrating to pancreatic and superficial lymph nodes
(data not shown). However, B cell depletion significantly reduced
the frequency of proliferating BDC2.5 CD4 T cells (42  6%; P 
0.05; Fig. 4A Left) and the total relative extent of labeled CD4 T
cell proliferation within pancreatic lymph nodes (Fig. 4B), whereas
BDC2.5 CD4 T cell proliferation was not detected in superficial
lymph nodes or spleen of either group of recipients (Fig. 4A Right
and data not shown). Thus, B cell depletion reduced autoreactive
T cell proliferation in response to endogenous autoantigens.
The role of B cells in CIA was assessed in DBA/1J mice treated
with CD20 or control mAb before collagen immunization as
described in ref. 24. DBA/1J mice have a high penetrance of arthritis
after heterologous collagen immunizations (25). CD4 T cells were
purified from draining lymph nodes 14 days after immunization,
with collagen-specific T cell proliferation being quantified in vitro.
Responses of CD4 T cells to recall collagen challenge at 10 and
100 g/ml were reduced by 61  8% and 60  2%, respectively, in
B cell-depleted mice when compared with control mAb-treated
littermates (Fig. 4C Left), whereas polyclonal mitogen-induced
proliferation remained intact (Fig. 4C Right). Thus, B cell depletion
inhibited collagen-specific CD4 T cell proliferation in response to
autoantigen challenge.
Discussion
This study demonstrates that B cell depletion in mice with otherwise
intact immune systems significantly reduced CD4 T cell responses
to foreign and self antigens, whereas CD8 T cell reactivity was
unaffected (Figs. 1 and 4). B cell depletion also reduced the
conversion of CD4 T cells from a naive CD44lowCD62Lhigh
phenotype to a memory CD44highCD62Llow phenotype in response
to Listeria challenge, whereas CD8 T cell phenotypes were only
modestly affected (Fig. 2). These effects likely result from the
absence of B cell and antigen-specific CD4 T cell interactions
because CD20 expression and mAb-mediated depletion were re-
stricted to mature B cells (SI Fig. 5 and Table 1). Moreover,
circulating and tissue T cell numbers, subsets, and phenotypes were
not affected by short-term B cell depletion (SI Fig. 6 B–D and Table
1), and ex vivo T cell proliferation in response to polyclonal stimuli
remained intact in the absence of B cells (SI Fig. 6C). Consistent
with the established role of DCs in T cell activation, both B cells and
DCs were required for optimal CD4 T cell activation (Fig. 3). This
suggests that CD20 mAb-induced changes in lymphoid tissue
architecture (11) do not eliminate DC and CD4 T cell interactions,
their respective functions, or their migration. Moreover, CD20
mAb-induced B cell depletion and monocyte activation did not
result in the release of inflammatory cytokines into the serum that
could affect T cell responses (SI Fig. 6A). Therefore, B cell
depletion had specific and selective effects on CD4 T cell
responses in vivo.
Inhibiting autoantigen-specific CD4 T cell activation may elu-
cidate the therapeutic benefit of B cell depletion in both the CIA
and NOD mouse models. Arthritogenic collagen-specific CD4 T
cells are essential for CIA induction, perpetuation, and exacerba-
tion (26). CD20 mAb-mediated B cell depletion significantly delays
CIA development whether B cells are depleted before collagen
immunizations, with modest effects once arthritis first appears (12).
Therefore, therapeutic B cell depletion may prevent disease by
Fig. 3. Both B cells and DCs contribute to CD4 T cell
expansion in vivo. (A) DT depletion of CD11c DCs in
CD11c–DTR mice. WT or CD11c–DTR mice were given
DT or PBS. Splenocytes were harvested 10 h later and
stained for CD11c and B220 expression. Frequencies of
DCs are indicated by the gated subpopulations. (B and
C) CD4 and CD8 T cell proliferation in vivo after B cell
and/or DC depletion and Listeria infection. OT-II
Thy1.1 CD4 cells or OT-I Thy1.1 CD8 cells were
CFSE-labeled and transferred into Thy1.2 recipients.
WT recipients were treated with control or CD20 mAb,
whereas CD11c–DTR mice were treated with DT (DC-
depleted) or DT and CD20 mAb (DC- and B cell-
depleted). One day after T cell adoptive transfer, mice
were infected with Listeria. At day 7 after infection,
splenocytes were harvested to analyze divisions of
donor cells. The thin lines represent adoptively trans-
ferred T cells without Listeria infection. The bar graphs
show CFSE geometric (Geo) mean fluorescence of the
whole histogram, which is inversely proportional to
cell divisions. The data are representative of two ex-
periments with three mice in each group. Significant
differences between means are indicated: *, P  0.05;
**, P  0.01.









reducing collagen-specific CD4 T cell activation (Fig. 4C) in
addition to inhibiting autoantibody production. Likewise, B cell
depletion delayed autoreactive CD4 T cell expansion in response
to islet  cell autoantigens in NOD mice (Fig. 4B). Inhibiting
autoantigen-specific T cell activation by B cell depletion may
explain diabetes prevention in mature NOD mice with otherwise
intact immune systems (Y. Xiu, C. P. Wong, J.-D.B., Y. Hamaguchi,
Y.W., S. M. Pop, R.M.T., and T.F.T., unpublished work).
In both the CIA and NOD mouse models, B cell depletion from
birth ameliorates disease (27–29). Studies demonstrating a role for
B cells in CD4 T cell priming have also predominantly used mice
given anti-IgM antibody since birth (30–33) or mice with genetic
defects in B cell development (34). In some studies, the absence of
B cells can impair CD4 T cell priming (28, 31, 32, 35, 36), whereas
in other studies, CD4 T cell priming was not affected (7, 37–40).
However, the absence of B cells during mouse development results
in significant quantitative and qualitative abnormalities within the
immune system, including a remarkable decrease in thymocyte
numbers and diversity (41), significant defects within spleen DC
and T cell compartments (7, 42, 43), an absence of Peyer’s patch
organogenesis and follicular DC networks (44, 45), and an absence
of marginal zone and metallophilic macrophages, with decreased
chemokine expression (43, 45). That T cell numbers and function
appear intact in mature mice after CD20 mAb-mediated B cell
depletion demonstrates that B cells are critical for normal immune
system development but not its maintenance. Thus, induced B cell
depletion in mice with intact immune systems may dampen some
cell-mediated immune responses without the pleiotropic effects
induced by congenital B cell depletion.
The current B cell depletion studies demonstrate that both B cells
and DCs are essential for optimal CD4 T cell responses (Fig. 3).
Although an intact B cell compartment was unable to support
optimal CD4 T cell activation when DCs were depleted, B cells
were not required for CD4 T cell proliferation in vivo after
high-dose OVA challenge (100 g; Fig. 1B). However, low-dose
OVA challenge (1–10 g; Fig. 1B) and Listeria infection (Fig. 1C)
required B cells for optimal CD4 T cell activation in vivo. B cells
were also required for optimal CD4 T cell activation in response
to high-dose KLH challenge in vivo (100 g) when assessed in vitro
by using restimulation assays with exogenous B cells as antigen-
presenting cells (Fig. 1A). That B cells may be required for effective
low-dose antigen recognition in vivo may reflect a functional
balance between DCs, B cells, and other antigen-presenting cell
populations. This balance is most likely influenced by the molecular
nature of the antigen being presented, its concentration and route
of exposure, and the adjuvants present. Additionally, DCs may
prime naı̈ve CD4 T cells in vivo, whereas B cells may have specific
roles in stimulating antigen-specific CD4 T cell proliferation after
activation by DCs (40).
B cell depletion therapy most likely affects autoimmune disease
onset by regulating CD4 T cell expansion, thereby delaying the
inflammatory phase of disease that leads to tissue destruction and
pathology. That B cells provided extra and essential functions over
and above those provided by DCs for CD4 T cell activation in
response to low-level antigen may be important during early
autoimmune disease development, when continuous waves of low-
level self-antigen stimulation occur. The effects of B cell depletion
on CD4 T cell activation may explain rare infections in lymphoma
patients receiving rituximab with microorganisms generally asso-
ciated with T cell immunosuppression such as Jamestown Canyon
(JC) papovavirus, CMV, or parvovirus B19 (46). B cell depletion
may also have other unanticipated effects on T cell effector
functions including the growth regulation of non-B cell malignan-
cies. An optimal therapy for disease quiescence may not only
require the effective elimination of mature B cells but may also
require continuous B cell depletion because environmental triggers
are likely to persist indefinitely. Nonetheless, it must be taken into
account that autoimmune disease patients are normally given CD20
mAb in combination with immunosuppressive drugs (47). In rheu-
matoid arthritis, rituximab is often administered in combination
Fig. 4. B cell depletion inhibits autoantigen-driven CD4 T cell expansion in vivo. (A) B cell depletion impairs  cell-specific CD4 T cell expansion in pancreatic
lymph nodes of NOD mice. CFSE-labeled BDC2.5 CD4 cells were transferred into NOD recipients that had been treated with CD20 or control (CTL) mAb 7 days
earlier. Four days later, pancreatic and superficial lymph node cells were stained for V4/CD4 expression and analyzed for CFSE flourescence intensity by flow
cytometric analysis. Representative CFSE profiles are shown. (B) Mean CFSE geometric mean fluorescence intensities ( SEM) for CD20 (open bars) and control
(closed bars) mAb-treated mice shown in A. (C) B cell depletion impairs CD4 T cell proliferation in response to collagen immunization. CD20 (open circles) or
control (filled circles) mAb-treated DBA/1J mice were immunized with collagen to induce arthritis. Fourteen days later, CD4 T cells were purified from draining
lymph nodes and incubated with collagen plus mitomycin C-treated B cells from control mice (Left) or stimulated with CD3 mAb (Right). Values represent mean
( SEM) [3H]thymidine uptake from triplicate cultures. (A–C) All data represent results obtained in at least four mice for each group. Significant differences
between samplemeans are indicated: **, P  0.01.
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with methotrexate. Therefore, the synergistic combination of B cell
depletion and immunosuppression of T cell activation may lead to
more significant clinical effects than B cell depletion alone. For
example, B cell depletion may block nascent autoantigen-specific T
cell activation and autoantibody development, whereas immuno-
suppression may arrest the clonal expansion of existing autoreactive
lymphocytes, thereby ameliorating disease progression. Although
multiple factors contribute to autoimmune disease pathogenesis,
this insight into the potential mechanism of action for CD20
immunotherapy may lead to the development of additional thera-
peutic strategies for autoimmune disease management.
Materials and Methods
Mice and Immunotherapy. C57BL/6, B6.PL THy1a/Cy (B6.Thy1.1), DBA/1J, NOD/
LtJ, C57BL/6-Tg(TcraTcrb)425Cbn/JB6 (OT-II), and C57BL/6-Tg(TcraTcrb)1100Mjb/J
(OT-I)werefromTheJacksonLaboratory.OT-IIandOT-I transgenicmicegenerate
CD4 and CD8 T cells that respectively respond to peptide 323–339 and 257–264
of OVA (18, 19). OT-II and OT-I mice (Thy1.2) were crossed to B6.Thy1.1 mice to
generate Thy1.1-expressing T cells for adoptive transfer experiments. CD20/
mice were as described in ref. 48. NOD.Cg-Tg(TcraBDC2.5)1Doi
Tg(TcrbBDC2.5)2Doi/DoiJ mice (BDC2.5) (49) were housed and bred at the Uni-
versity of North Carolina at Chapel Hill. CDB6.FVB-Tg(Itgax-DTR/EGFP)57Lan/J
(B6.CD11c DT receptor transgenic mice, CD11c–DTR) as originally described were
provided by M. D. Gunn (Duke University). To deplete CD11c DCs in vivo,
CD11c–DTR transgenic mice were treated i.p. with 100 ng DT (Sigma) in 200 l of
PBS as described in ref. 22. To induce in vivo B cell depletion, sterile CD20
(MB20-11, IgG2c) or isotype-matched control mAbs (250 g) were injected in 200
l of PBS through lateral tail veins (9). All mice were bred in a specific pathogen-
free barrier facility and used at 8–12 weeks of age unless otherwise noted. Duke
University and University of North Carolina, Chapel Hill, Animal Care and Use
Committees approved all studies.
Immunizations and in Vitro T Cell Proliferation Assays. For KLH assays, mice were
injected s.c. with KLH (100 g; endotoxin free; Sigma) in complete Freund’s
adjuvant (Sigma). After 7 days, 3  105 purified CD4 or CD8 T cells harvested
from draining lymph nodes were cultured in 96-well plates in 200 l of complete
RPMI1640culturemediumwith1.5105 mitomycinC-treated(Sigma)Bcellsand
KLH (0, 1, and 10 g/ml). Collagen immunizations in male DBA1/J mice used type
II chicken collagen (Chondrex) dissolved in 10 mM acetic acid solution (5 mg/ml)
overnight at 4°C. Dissolved collagen (100 g) was emulsified with an equal
volume of complete Freund’s adjuvant, with 100 l being injected s.c. into the
base of the tail. For collagen-specific CD4 T cell proliferation, draining lymph
nodes were harvested 14 days after collagen immunization, with 5  105 T cells
being cultured with 1  106 mitomycin C-treated (Sigma) B cells and T cell
proliferation grade type II collagen (0, 10, and 100 g/ml; Chondrex), as recom-
mended by the manufacturer. Proliferation was measured by [3H]thymidine
incorporation during the final 12-h of 4-day cultures, followed by scintillation
counting. Insomeexperiments, thymidine incorporationwasmeasuredafter48h
of CD4 T cell stimulation with tissue culture plate-bound CD3 mAb (5 g/ml; BD
PharMingen).
Adoptive Transfer Experiments. Donor Thy1.1 OT-II CD4 or OT-I CD8 T cells
from pooled spleens and lymph nodes were labeled with CFSE fluorescent dye (1
M;VybrantCFDASE; Invitrogen–MolecularProbes)accordingtotheinstructions
of the manufacturer. Labeled Thy1.1 cells (5  106) were given i.v. to Thy1.2
congenic recipients. Recipient mice were immunized i.p. with alum precipitated
OVA (Sigma) or were given Listeria monocytogenes producing OVA peptide
(aminoacids134–387)capableofactivatingbothOT-IICD4 andOT-ICD8 Tcells
(20). Bacteria were grown in brain–heart infusion media supplemented with 5
g/ml erythromycin (Sigma), with 5  105 colony-forming units (0.1 LD50)/mouse
in 200 l of PBS injected i.v. (lateral tail vein). The proliferation of transferred cells
was visualized by flow cytometric analysis of 1  104 CFSE-labeled Thy1.1 cells.
Transferred OT-II CD4 or OT-I CD8 T cells were identified by Thy1.1 and CD4 or
CD8 mAb staining, respectively. For adoptive transfer experiments involving
BDC2.5 CD4 T cells, 2  106 CFSE-labeled cells were injected i.v. into female NOD
recipients, and T cell proliferation was analyzed after staining with CD4 and V4
mAbs.
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